非小细胞肺癌组织中丝苏氨酸激酶11与细胞死亡调解子抗体表达检测的临床意义

Clinical Significance of Detection of the Expression for the STK11 and BIM in Non-small Cell Lung Cancer

目的探讨非小细胞肺癌组织中丝苏氨酸激酶11（STK11）、细胞死亡调解子抗体（BIM）表达检测的临床意义。方法选取2014年3月至2015年3月河北省胸科医院接收的非小细胞肺癌患者65例，收集切除后的非小细胞肺癌组织标本及癌旁正常组织。采用免疫组织化学技术对标本中STK11、BIM的表达进行研究。结果非小细胞肺癌组织中的STK11阳性表达率低于旁癌组织[63．08％（41／65）比92．31％（60／65）]（x^2=16．022，P〈0．05），非小细胞肺癌组织中的BIM的阳性表达率高于旁癌组织[61．54％（40／65）比21．54％（14／65）]（x^=21．413，P〈0．05）。淋巴结转移患者非小细胞肺癌组织中STK11阳性表达率显著低于未转移淋巴结患者[41．38％（12／29）比80．56％（29／36）]（P〈0．05）；Ⅰ～Ⅱ期患者非小细胞肺癌组织中STK11的阳性表达率显著高于Ⅲ～Ⅳ期[72．55％（37／51）比28．57％（4／14）]（P〈0．05）；高分化患者的非小细胞肺癌组织中STK11阳性表达率显著高于中分化、低分化[89．47％（17／19）比51．61％（16／31）、53．33％（8／15）]（P〈0．05）。腺癌患者非小细胞肺癌组织中STK11阳性率显著高于鳞癌[78．13％（25／32）比48．48％（16／33）]（P〈0．05）。Ⅰ～Ⅱ期的BIM阳性表达率显著高于Ⅲ～Ⅳ期[70．59％（36／51）比28．27％（4／14）]（P〈0．05）；高分化患者非小细胞肺癌组织阳性表达率显著高于中分化、低分化[89．47％（17／19）比45．16％（14／31）、60．oo％（9／15）]（P〈0．05）。腺癌BIM阳性率高于鳞癌[75．oo％（24／32）比48．48％（16／33）]（P〈O．05）。结论STK11、BIM表达水平可作为判定非小细胞肺癌转移及预后的生物学指标。

Objective To explore the clinical significance of detection of the expression of serine/threo- nine protein kinase 11 （ STK11 ）, Bcl-2 interacting mediator of cell death （BIM） in non-small cell lung cancer （NSCLC）. Methods Total of 65 NSCLC patients in Hebei Provinical Chest Hospital from Mar. 2014 to Mar. 2015 were included in the study, the dissected cancerous tissue sample and the paracancerous tissue were collected. Immunohistochemical techniques was used to study the expression of STK11, BIM in the protein samples. Results STK11 positive expression rate of the cancer tissue was lower than the paracancerous tissue [ 63.08 % （41/65） vs 92. 31% （60/65） ] （x^2 = 16. 022, P 〈 0.05 ）, the BIM positive expression rate of the cancerous tissue was higher than the paracancerous tissue[61.54% （40/65） vs 21.54% （ 14/65 ） ] （x^2 = 21. 413, P 〈 0.05 ）. Tissues STK11 positive expression rate in in patients with lymph node metastasis was significantly lower than patients without lymph nodes metastasis [41.38% （12/29） vs 80. 56% （29/ 36 ） ] （ P 〈 0. 05 ） ; STK11 positive rate in stage I - II patients was significantly higher than that of stage Ⅲ - Ⅳ patients [ 72.55 % （ 37/51 ） vs 28.57 % （4/14） ] （ P 〈 0. 05 ） ; STK11 positive expression rate of patients of higher differentiation was significantly higher than patients with medium and low differentiation [ 89.47 % （17/19） vs 51.61% （ 16/31 ） ,53.33% （8/15） ] （P 〈0. 05 ）. STKll in patients with adenocarcinoma was significantly higher than patients with squamous cell carcinomas [ 78. 13% （ 25/32 ） vs 48.48% （ 16/33 ） （ P 〈0. 05 ）. BIM positive expression rate of stage I - II patients was significantly higher than that of Ill -IV [ 70. 59% （36/51 ） vs 28.27% （4/14） 1 （P 〈 0.05 ） ;the BIM positive expression rate of patients with high differentiation was significantly higher than patients with medium and low differentiation [ 89.47% （ 17/19 ） vs 45. 16% （ 14/31 ） ,60.00% （ 9/15 ） ] （ P 〈 O. 05 ）. Adenocarcinoma BIM positive rate was higher than squamous cell carcinoma [ 75.00% （24/32） vs 48.48 % （ 16/33 ） ] （ P 〈 0.05 ）. Conclusion The STK11, BIM expression levels can be used as biological indicators for the metastasis and prognosis of NSCLC.